

134. doi:10.1530/EJE-18-0749.
7. Colao A, Pivonello R, Scarpa R, et al. The acromegalic arthropathy. *J Endocrinol Invest*. 2005;28(8 Suppl.):24-31.
8. Drummond J, Roncaroli F, Grossman AB, et al. Clinical and Pathological Aspects of Silent Pituitary Adenomas. *J Clin Endocrinol Metab*. 2019;104(7):2473-2489. doi:10.1210/jc.2018-00688.
9. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. *Cancer*. 2004;101(3):613-619. doi:10.1002/cncr.20412.
10. Fassett DR, Couldwell WT. Metastases to the pituitary gland. *Neurosurg Focus*. 2004;16(4):E8.
11. Guerrero-Perez F, Marengo AP, Vidal N, et al. Primary tumors of the posterior pituitary: a systematic review. *Rev Endocr Metab Disord*. 2019;20(2):219-238. doi:10.1007/s11154-019-09484-1.
12. Chen J, Jian X, Deng S, et al. Identification of recurrent USP48 and BRAF mutations in Cushing's disease. *Nat Commun*. 2018;9(1):3171. doi:10.1038/s41467-018-05275-5.
13. Kaltsas GA, Powles TB, Evanson J, et al. Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. *J Clin Endocrinol Metab*. 2020;85(4):1370-1376. doi:10.1210/jcem.85.4.6501.
14. Kwacharoen R, Blitz AM, Tavares F, et al. Clinical features of sellar and suprasellar meningiomas. *Pituitary*. 2014;17(4):342-348. doi:10.1007/s11102-013-0507-z.
15. Lavrentaki A, Paluzzi A, Wass JA, et al. Epidemiology of acromegaly: review of population studies. *Pituitary*. 2017;20(1):4-9. doi:10.1007/s11102-016-0754-x.
16. Lopes MB, Sloan E, Polder J. Mixed Gangliocytoma-Pituitary Adenoma: Insights on the Pathogenesis of a Rare Sellar Tumor. *Am J Surg Pathol*. 2017;41(5):586-595. doi:10.1097/PAS.0000000000000806.
17. Lu L, Wan X, Xu Y, et al. Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions. *Diagnostics (Basel)*. 2022;12(4). doi:10.3390/diagnostics12040977.
18. McDowell BD, Wallace RB, Carnahan RM, et al. Demographic differences in incidence for pituitary adenoma. *Pituitary*. 2011;14(1):23-30. doi:10.1007/s11102-010-0253-4.
19. Mete O, Lopes MB, Asa SL. Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituitary. *Am J Surg Pathol*. 2013;37(11):1694-1699. doi:10.1097/PAS.0b013e31829723e7.
20. Muller HL, Merchant TE, Warmuth-Metz M, et al. Craniopharyngioma. *Nat Rev Dis Primers*. 2019;5(1):75. doi:10.1038/s41572-019-0125-9.
21. Neou M, Villa C, Armignacco R, et al. Pangenomic Classification of Pituitary Neuroendocrine Tumors. *Cancer Cell*. 2020;37(1):123-134 e125. doi:10.1016/j.ccell.2019.11.002.
22. Nishioka H, Inoshita N, Mete O, et al. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. *Endocr Pathol*. 2015;26(4):349-355. doi:10.1007/s12022-015-9398-z.
23. Ostrom QT, Francis SS, Barnholtz-Sloan JS. Epidemiology of Brain and Other CNS Tumors. *Curr Neurol Neurosci Rep*. 2021;21(12):68. doi:10.1007/s11910-021-01152-9.
24. Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. *Neuro Oncol*. 2018;20(suppl_4):iv1-iv86. doi:10.1093/neuonc/now131.
25. Papanikolaou N, Millar O, Coulden A, et al. Clinical characteristics of functioning gonadotroph adenoma in women presenting with ovarian hyperstimulation: Audit of UK pituitary centres. *Clin Endocrinol (Oxf)*. 2023;99(4):386-395. doi:10.1111/cen.14949.
26. Ragnarsson O, Olsson DS, Chantzichristos D, et al. The incidence of Cushing's disease: a nationwide Swedish study. *Pituitary*. 2019;22(2):179-186. doi:10.1007/s11102-019-00951-1.
27. Shimon I. Metastatic Spread to the Pituitary. *Neuroendocrinology*. 2020;110(9-10):805-808. doi:10.1159/000506810.
28. Schmid S, Solomon DA, Perez E, et al. Genetic and epigenetic characterization of posterior pituitary tumors. *Acta Neuropathol*. 2021;142(6):1025-1043. doi:10.1007/s00401-021-02377-1.
29. Teeles RJ, Silverman EM. Clinicopathologic review of 88 cases of carcinoma metastatic to the pituitary gland. *Cancer*. 1975;36(1):216-220. doi:10.1002/1097-0142(197507)36:1<216:aid-cncr2820360123>3.0.co;2-e.
30. Trouillas J, Roy P, Sturm N, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. *Acta Neuropathol*. 2013;126(1):123-135. doi:10.1007/s00401-013-1084-y.
31. Villa C, Vasiljevic A, Jaffrain-Rea ML, et al. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. *Virchows Arch*. 2019a;475(6):687-692. doi:10.1007/s00428-019-02655-0.
32. Villa C, Vasiljevic A, Jaffrain-Rea ML, et al. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. *Virchows Arch*. 2019 b. doi:10.1007/s00428-019-02655-0
33. WHO. (2021). World Health Organization Classification of Tumours of the Central Nervous System. (5th ed.). Lyon: International Agency for Research on Cancer.

ON-LINE KURZ

Propojení Fabryho choroby: diagnostika a léčba u pacientů s Fabryho chorobou



OBSAH KURZU

- ▶ **Teoreticky o Fabryho chorobě** – MUDr. Kristýna Bayerová, Centrum pro Fabryho chorobu, VFN Praha
- ▶ **Jak nepřehlédnout pacienta – s Fabryho chorobou v praxi kardiologa?** – MUDr. Mária Vyskočilová, FN Brno
- ▶ **Prakticky o Fabryho chorobě** – MUDr. Kristýna Bayerová, Centrum pro Fabryho chorobu, VFN Praha
- ▶ **Diskuze**
- ▶ **Fabryho choroba** – MUDr. Gabriela Dostálová, II. interní klinika – Kardiologie a angiologie 1. LF UK a VFN v Praze

ODBORNÝ GARANT:

prof. MUDr. Aleš Linhart, DrSc.

POŘADATEL:

Společnost SOLEN, s. r. o.,
ve spolupráci s II. interní klinikou kardiologie a angiologie 1. LF UK a VFN v PrazePOČET
KREDITŮ **2**Registrace
ZDARMATERMÍN
duben 2024
až březen 2025
dostupný na
online.solen.czZLATÝ
PARTNER

sanofi

